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Objectives: Report baseline patient characteristics of the CAMPOS study, which 
is evaluating the PMO care map in Swiss clinical practice. MethOds: Between 
June 2012„ŸMay 2013, specialist osteoporosis centers operating a DXA machine 
enrolled women diagnosed with PMO who initiated intravenous (IV) ibandronate 
or zolendronate, or subcutaneous (SC) denosumab (index date) within 6 months 
prior to center initiation. Study outcomes are recorded at index date (baseline) 
and any visit in the 24-month observation period thereafter, as available from rou-
tine practice. Results: Twenty-one centers, mainly in urban regions (81%), of a 
non-academic nature (76%), and specializing in rheumatology (71%), recruited 275 
women. Two-hundred-sixty-three met the inclusion criteria and were included in 
this baseline analysis; 180 (68%) of these received follow-up care at the specialist 
center and 83 (32%) were referred back to general practice. At baseline, mean (SD) 
age was 70.9 (9.7) years and mean time since diagnosis 5.4 (5.4) years (n= 248). The 
following diagnostic parameters and risk factors were assessed at the time of PMO 
diagnosis: prior osteoporotic fracture, 258 [94%] patients, with 60% reporting this 
risk factor; DXA bone mineral density (BMD) scan, 255 (97%) patients (hip and either 
lumbar spine or forearm BMD measured in 231 [88%] patients), mean (SD) BMD 
T-scores at the femoral neck and lumbar spine -2.34 (0.79; n= 230) and -2.89 (1.28; 
n= 232), respectively; calcium and vitamin D status, 260 (99%) patients; fracture 
history, 258 [98%] patients. cOnclusiOns: In the current study, prevalent frac-
tures were assessed in almost all women initiating IV ibandronate or zolendronate, 
or SC denosumab, and the majority reported at least one prior fracture. Calcium 
and vitamin D status, DXA BMD scans and/or fracture history were also routinely 
assessed at PMO diagnosis.
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Objectives: Osteoarthritis (OA) and the demand for OA care are increasing with 
the aging population. Policy-makers seek to identify policies to sustainably manage 
this growing demand, yet envisioning the short- and long-term effects of policy 
options is difficult within chronic care. We aimed to develop a decision-support 
tool enabling policy-makers to explore policies and their effects. MethOds: We 
developed a system dynamics (SD) simulation of patient flow across the continuum 
of OA care in Alberta: from self-directed to primary and specialist care, through 
surgical interventions, post-surgical follow-up and subsequent re-operations. The 
simulation was developed using SD modeling principles and an iterative, integrated 
knowledge translation process, including multiple workshops with clinicians and 
administrators to define the problem, system boundaries and current patient flow. 
The resulting simulation was populated with data extracted from administrative 
databases (e. g. physician claims, inpatient records). Results: The model yields 
patient population, OA care resource requirements and associated cost results at 
each stage of care over 10 years by region and patient characteristics (e. g. sex). If 
current practices continue, annual hip and knee replacement surgery volumes are 
estimated to increase by more than 5,000 between 2015 and 2025. If a 14 week surgi-
cal wait-time is implemented in 2015, 600 additional surgeries must be performed 
in the first year to “catch-up” on the existing surgical queue, yet long-term surgery 
rates are similar to those without the wait-time target. The costs of the additional 
surgeries are partly offset by the savings achieved by fewer patients requiring care 
while awaiting surgery. cOnclusiOns: This simulation can be used as a decision-
support tool to estimate changes in patient populations, resource requirements 
and costs over time that may result from various OA management scenarios. Such 
results can equip policy makers with additional evidence to make more informed 
OA care policy decisions.
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Objectives: Osteoporosis is an important public health issue due to its rising preva-
lence and excess morbidity and mortality among this population. The present study 
aimed to demonstrate the use of clinical data repository in Israel’s second largest 
health organization (Maccabi Healthcare Services) to establish a registry of osteopo-
rosis patients and assess its early findings with respect to the epidemiology and bur-
den of the disease, high risk populations, and quality of care. MethOds: Included 
in the registry are patients with history of osteoporosis diagnosis, typical fractures 
(e. g. closed fractures of proximal femur, vertebral, Colles’ and proximal humerus) 
and or purchases of relevant medications, documented since 2000. In addition, we 
included patients with low bone density from over 140,000 measurements, using an 
Objectives: To estimate future scenarios of utilization of knee arthroplasty (KA) 
revision in the Spanish National Health System at the short and long term and its 
impact on primary KA utilization. MethOds: A discrete event simulation model 
was built to represent the utilization of KA for 20 years (2011–2031) in the Spanish 
National Health System, especially the burden of KA revision according to differ-
ent scenarios of utilization and protheses survival. Data on KA utilization from 
1997 to 2011 was obtained from the Spanish Minimum Data Set. Three scenarios 
of future utilization of primary KA were estimated: 1) fixed number since 2011; 2) 
fixed age and sex adjusted rates since 2011; and 3) projection using a linear regres-
sion model. These three scenarios were combined with two prostheses survival 
functions L) from a study including primary KA from 1995 to 2000; and H) from 
the Catalan Registry of Arthroplasty, including primary KA from 2005 to 2013. The 
model was programmed using ARENA. The simulation results were analyzed at the 
short (2015) and long-term (2030). Results: Variations in the number of revisions 
depended on both the primary utilization rate and the survival function applied, 
ranging from 8.3% to 31.6% increase at the short-term and from 38.3% to 176.9% 
at the long term, percentages corresponding to the combinations of scenario 1 
(low primary utilization rate) and survival function H (better survival) versus sce-
nario 3 (high primary utilization rate) and survival function L (worse survival), 
respectively. The prediction of increase on overall surgeries ranged from 0.1% to 
22.3% at the short-term and from 3.7% to 98.2% at the long-term. cOnclusiOns: 
Projections of the burden of knee arthroplasty provide a quantitative basis for 
future policy decisions relating to concentration of high complexity procedures, 
the number of orthopaedic surgeons required to perform these procedures and 
the number of resources needed.
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Objectives: Cachexia is a medical syndrome associated with several chronic 
health conditions including many cancers, COPD, HIV, and kidney disease. 
Cachexia is a wasting type syndrome characterized as a loss in body mass or 
metabolic dysfunction. The loss in mass is associated with decreases in strength 
and functional capacity. Currently there is little research into cachexia and our 
objective is to characterize cachexia patients, their health care utilization and 
costs. MethOds: For this study we utilized one year (2009) of the Nationwide 
Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% 
sample of hospitals within the United States. We grouped cachexia individuals 
by primary or secondary diagnosis and then compared those with cachexia to all 
others in terms of length of stay (LOS) and total cost. Finally we looked into factor 
predicting increased LOS using a negative binomial model. Results: We esti-
mated US prevalence for cachexia related admissions at 161,898 cases. Cachexia 
patients were older with an average age of 67.95 versus 48.10 in their non-cachexia 
peers. Hospitalizations associated with cachexia had an increased LOS compared 
to non-cachexia patients (6 days versus 3) with average costs per stay $4,641.30 
greater. Differences were seen in loss of function (LOF) with cachexia patients 
mostly in the major LOF category (52.60%) whereas non-cachexia patients were 
spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%). 
Significant positive predictors of increased LOS among cachexia patients included 
urban hospital (IRR= 1.21 non-teaching urban, IRR= 1.23 teaching urban), having 
either major (IRR= 1.41) or extreme (IRR= 2.64) LOF, and having a primary diagnosis 
of pneumonia (IRR= 1.15). cOnclusiOns: Cachexia is a diverse syndrome associ-
ated with a number of chronic diseases. We have characterized cachexia and seen 
it associated with increased length of stay, increased cost, and more severe loss 
of function compared to those without cachexia.
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Objectives: To describe baseline characteristics and changes in BMD T-scores at 
1 year, in postmenopausal women with OP receiving 2 denosumab injections in 
routine clinical practice in Bulgaria. MethOds: This retrospective observational 
study, conducted in 11 specialist (endocrinology or rheumatology) practices scat-
tered geographically across Bulgaria, included postmenopausal women ≥ 50 years 
old with a clinical diagnosis of OP, who initiated denosumab 60 mg Q6M on or after 
Oct 2011 (regulatory approval of denosumab in Bulgaria) and received a follow-up 
injection within 7 months (until Aug 2013). All study outcomes were recorded as per 
routine clinical practice/reimbursement requirements, with BMD T-scores recorded 
(at ≥ 1 site) at first denosumab injection (baseline) and 1-year follow-up. Descriptive 
statistics were conducted. Results: 222 women met the inclusion criteria with a 
mean (SD) age of 64.2 (±8.54) years; approximately half (49.5%) were < 65 years old 
and13.1% ≥ 75 years. Mean (SD) age at menopause was 48.1 (±3.98) years. 26.6% 
reported a prior fragility fracture, with vertebral the most common site (71.2%) 
followed by hip (6.8%) and other sites (32.2%, excluding hip). At baseline, 2.7% were 
receiving vitamin D only, 5.9% calcium supplements only and 35.1% both; 31.5% had 
received prior OP therapy. At baseline, mean (SD) BMD T-score was -3.2 (±0.63) at 
the lumbar spine (LS; n= 189), -2.3 (±0.81) at the total hip (TH; n= 75) and -2.7 (±0.71) 
at the femoral neck (FN; n= 137). At 1-year follow-up, all women had BMD assessed 
at ≥ 1 site; T-scores increased to -2.7 (±0.57) at the LS (n= 187), -2.1 (±0.91) at the TH 
(n= 65) and -2.4 (±0.68) at the FN (n= 123). cOnclusiOns: Postmenopausal women 
with OP receiving 2 denosumab injections in Bulgarian clinical practice had a mean 
age of 64.2 years and experienced improved mean BMD T-scores at the LS, TH, and 
FN after 1 year. Study funded by Amgen.
